Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP7 | Q9UHL4 | 5/20 | 0.46 |
| ▸ | DPP8 | Q6V1X1 | 5/20 | 0.46 |
| ▸ | DPP9 | Q86TI2 | 5/20 | 0.46 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.42 |
| ▸ | RRM1 | P23921 | 1/20 | 0.42 |
| ▸ | GSR | P00390 | 1/20 | 0.41 |
| ▸ | RIMKLA | Q8IXN7 | 1/20 | 0.39 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.39 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.39 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.39 |
| ▸ | DPP4 | P27487 | 2/20 | 0.39 |
| ▸ | NRP1 | O14786 | 1/20 | 0.38 |
| ▸ | GNPAT | O15228 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29775575 | 1.00 | DPP7 (0.46) | DPP7DPP8DPP9FOLH1RRM1 | |
| SCHEMBL31143777 | 0.96 | DPP7 (0.44) | DPP7DPP8DPP9FOLH1RRM1 | |
| SCHEMBL30439292 | 0.96 | DPP7 (0.44) | DPP7DPP8DPP9FOLH1RRM1 | |
| SCHEMBL30439668 | 0.91 | DPP7 (0.41) | DPP7DPP8DPP9FOLH1RRM1 | |
| SCHEMBL30439817 | 0.91 | GSR (0.50) | DPP7DPP8DPP9FOLH1RRM1 | |
| SCHEMBL30577902 | 0.91 | FOLH1 (0.50) | DPP7DPP8DPP9FOLH1RRM1 | |
| SCHEMBL31141346 | 0.90 | DPP9 (0.42) | DPP7DPP8DPP9FOLH1GSR | |
| SCHEMBL30368054 | 0.90 | DPP7 (0.45) | DPP7DPP8DPP9FOLH1RRM1 | |
| SCHEMBL30439787 | 0.90 | FOLH1 (0.46) | DPP7DPP8DPP9FOLH1RRM1 | |
| SCHEMBL31141348 | 0.89 | DPP7 (0.42) | DPP7DPP8DPP9FOLH1RRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4688802-A1 | CATIONIC LIPID FOR COVALENT MODIFICATION OF PEPTIDES | PharmaIN Corporation (US) | 2026-02-11 | — | — | EP | claimed |
| US-12448418-B2 | Activatable therapeutic peptides and uses thereof | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2025-10-21 | — | — | US | claimed |
| CN-118994310-B | Antibacterial short peptide with high protease stability, and preparation method and application thereof | 东北农业大学 | 2025-05-09 | — | — | CN | claimed |
| CN-119390776-A | Low-toxicity high-stability cyclic lipid antibacterial peptide and application thereof | 兰州大学 | 2025-02-07 | — | — | CN | claimed |
| WO-2024250929-A1 | GROUP OF CYCLIC ALKALINE LIPOPEPTIDE COMPOUNDS, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 中国医学科学院医药生物技术研究所 | 2024-12-12 | — | — | WO | claimed |
| CN-119101129-A | Cyclic alkaline lipopeptide compound and preparation method and application thereof | 中国医学科学院医药生物技术研究所 | 2024-12-10 | — | — | CN | claimed |
| CN-118994310-A | Antibacterial short peptide with high protease stability, and preparation method and application thereof | 东北农业大学 | 2024-11-22 | — | — | CN | claimed |
| WO-2024206903-A1 | CATIONIC LIPID FOR COVALENT MODIFICATION OF PEPTIDES | PHARMAIN CORPORATION (US) | 2024-10-03 | — | — | WO | claimed |
| US-20240325544-A1 | CATIONIC LIPID FOR COVALENT MODIFICATION OF PEPTIDES | PHARMAIN CORPORATION | 2024-10-03 | — | — | US | claimed |
| CN-118406117-A | Polypeptide for treating gram-negative bacterial infection, and preparation method and application thereof | 国家纳米科学中心 | 2024-07-30 | — | — | CN | claimed |
| US-20230365635-A1 | Activatable Therapeutic Peptides and Uses Thereof | MASSACHUSETTS INSTITUTE OF TECHNOLOGY | 2023-11-16 | — | — | US | claimed |
| WO-2023220501-A1 | ACTIVATABLE THERAPEUTIC PEPTIDES AND USES THEREOF | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2023-11-16 | — | — | WO | claimed |
| CN-116425838-A | Polypeptide compound and medical application thereof | 北京拓界生物医药科技有限公司 | 2023-07-14 | — | — | CN | claimed |
| EP-4132945-A2 | ANTIBACTERIAL LIPOPEPTIDES, PHARMACEUTICAL COMPOSITION AND COSMETIC COMPOSITION COMPRISING THEM, AND USES THEREOF | Uniwersytet Warszawski (PL) | 2023-02-15 | — | — | EP | claimed |
| EP-4725958-A1 | NOVEL DECAPEPTIDE AND USE THEREOF IN ANTIBACTERIAL | Methycure Biotech Corp. (CN) | 2026-04-15 | — | — | EP | disclosed |
| EP-4725957-A1 | GROUP OF CYCLIC ALKALINE LIPOPEPTIDE COMPOUNDS, AND PREPARATION METHOD THEREFOR AND USE THEREOF | Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences (CN) | 2026-04-15 | — | — | EP | disclosed |
| EP-4688802-A1 | CATIONIC LIPID FOR COVALENT MODIFICATION OF PEPTIDES | PharmaIN Corporation (US) | 2026-02-11 | — | — | EP | disclosed |
| CN-115298198-A | Novel compounds and compositions for targeted therapy of kidney-related cancers | 上海盟科药业股份有限公司 | 2022-11-04 | — | — | CN | disclosed |
| WO-2022206826-A1 | SULFATE OF POLYMYXIN DERIVATIVE AND PHARMACEUTICAL COMPOSITION THEREOF | 江苏奥赛康药业有限公司 | 2022-10-06 | — | — | WO | disclosed |
| CN-114148534-A | Patrol and examine unmanned aerial vehicle with indoor location structure | 国网山东省电力公司泰安供电公司 | 2022-03-08 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230365635-A1 | Activatable Therapeutic Peptides and Uses Thereof | TPX2, HM13, XPNPEP1 | DPP7 931/4885DPP8 668/4885DPP9 1367/4885 |
| US-12448418-B2 | Activatable therapeutic peptides and uses thereof | TPX2, HM13, XPNPEP1 | DPP7 931/4885DPP8 668/4885DPP9 1367/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.